| 51 |
20460535 | Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. | 2010 Jun 1 |
1 |
| 52 |
20850924 | MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. | 2010 Dec 28 |
4 |
| 53 |
19068089 | Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. | 2009 Feb |
1 |
| 54 |
19147762 | Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. | 2009 Jan 15 |
1 |
| 55 |
19188164 | MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. | 2009 Feb 1 |
1 |
| 56 |
19549370 | [Apoptosis of Burkitt's lymphoma Raji cell line induced by bortezomib]. | 2009 Jun |
2 |
| 57 |
19661301 | Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent. | 2009 Aug |
4 |
| 58 |
19934289 | Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. | 2009 Dec 1 |
3 |
| 59 |
18790767 | Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. | 2008 Sep |
1 |
| 60 |
17096161 | Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. | 2007 Jul |
1 |
| 61 |
17235352 | The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells. | 2007 Apr |
3 |
| 62 |
17363600 | The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. | 2007 Mar 15 |
2 |
| 63 |
17910628 | The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. | 2007 Nov |
1 |
| 64 |
16166592 | The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. | 2006 Jan 1 |
1 |
| 65 |
16849420 | Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. | 2006 Oct |
1 |
| 66 |
15662128 | The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. | 2005 Jan |
1 |
| 67 |
15830705 | Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines. | 2005 Winter |
4 |
| 68 |
15929791 | Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. | 2005 Jun 1 |
1 |
| 69 |
16091363 | Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function. | 2005 Oct 14 |
1 |
| 70 |
16178003 | Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. | 2005 Nov 1 |
1 |
| 71 |
16382051 | The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. | 2005 Nov |
1 |
| 72 |
14965369 | Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. | 2004 Feb |
2 |
| 73 |
15016328 | Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. | 2004 Mar |
1 |
| 74 |
15052205 | Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. | 2004 Apr |
1 |
| 75 |
15464472 | Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. | 2004 Oct |
1 |
| 76 |
15638966 | Use of proteasome inhibition in the treatment of lung cancer. | 2004 Dec |
1 |
| 77 |
12393500 | Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. | 2003 Feb 15 |
2 |
| 78 |
12631620 | Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. | 2003 Mar |
1 |
| 79 |
12821677 | Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. | 2003 Sep 5 |
2 |
| 80 |
14513055 | The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. | 2003 Oct |
1 |
| 81 |
14612532 | The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. | 2003 Nov 1 |
9 |
| 82 |
14688479 | Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. | 2003 Nov-Dec |
4 |
| 83 |
11306489 | The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. | 2001 Apr 1 |
2 |
| 84 |
11740818 | Novel therapies targeting the myeloma cell and its bone marrow microenvironment. | 2001 Dec |
2 |